Table 1.
Demographic and clinical characteristics in 24 hours prior and 48 hours after admission of patients not evaluated for AKI vs evaluated patients and the evaluated patients with and without AKI.
| Total Eligible Population | Evaluated Population | |||||
|---|---|---|---|---|---|---|
|
| ||||||
| Not Evaluated (n= 11,540) | Evaluated (n = 2,374) | P value | No AKI (n = 1,652) | AKI (n = 722) | P value | |
|
| ||||||
| Age (y) | 5.8 (1.8 – 11.9) | 8.8 (2.6 – 14.8) | < 0.0011 | 10.5 (3.3 – 15.2) | 5.3 (2.0 – 12.4) | < 0.0011 |
|
| ||||||
| Male sex | 6348 (55%) | 1271 (54%) | 0.22 | 858 (52%) | 413 (57%) | 0.022 |
|
| ||||||
| Race | < 0.0012 | 0.72 | ||||
| White | 8570 (74%) | 1830 (77%) | 1268 (77%) | 562 (78%) | ||
| Black | 1981 (17%) | 400 (17%) | 287 (17%) | 113 (16%) | ||
| Other# | 289 (3%) | 51 (2%) | 33 (2%) | 18 (2%) | ||
| Unknown | 700 (6%) | 93 (4%) | 64 (4%) | 29 (4%) | ||
|
| ||||||
| Hispanic/Latino | 1004 (9%) | 164 (7%) | < 0.0012 | 101 (6%) | 63 (9%) | 0.022 |
|
| ||||||
| Weight z-score | 0.3 (−0.6 – 1.1) | −0.1 (−1.1 – 0.8) | < 0.0011 | 0.0 (−0.9 – 0.9) | −0.4 (−1.4 – 0.6) | < 0.0011 |
|
| ||||||
| No. of Scr measurements during Admission* | 0: 7836 (68%); 1: 3704 (32%) | 2 (1 – 3) | < 0.0011 | 2 (1 – 2) | 3 (2 – 5) | < 0.0011 |
|
| ||||||
| Baseline Scr (mg/dL) | – | 0.37 (0.25 – 0.54) | – | 0.42 (0.29 – 0.58) | 0.26 (0.18 – 0.41) | < 0.0011 |
|
| ||||||
| Scr (mg/dL) | – | 0.50 (0.35 – 0.70) | – | 0.49 (0.34 – 0.68) | 0.53 (0.37 – 0.77) | < 0.0011 |
|
| ||||||
| WBC count (×103/μL) | 10.6 (7.7 – 14.7) | 9.2 (6.1 – 13.3) | < 0.0011 | 9.2 (6.4 – 12.8) | 9.3 (5.5 – 14.4) | 0.81 |
|
| ||||||
| Hematocrit (%) | 35 (31 – 38) | 33 (29 – 38) | < 0.0011 | 34 (29 – 38) | 33 (29 – 37) | 0.11 |
|
| ||||||
| Platelet count(×103/μL) | 288 (229 – 359) | 268 (195 – 359) | < 0.0011 | 271 (201 – 359) | 263 (176 – 360) | 0.091 |
|
| ||||||
| Total Medication Exposures | 2 (1 – 4) | 4 (2 – 7) | < 0.0011 | 4 (2 – 6) | 4 (2 – 7) | 0.0041 |
|
| ||||||
| Nephrotoxic Medication Exposures | 0 (0 – 1) | 1 (0 – 1) | < 0.0011 | 1 (0 – 1) | 1 (0 – 1) | 0.051 |
|
| ||||||
| Contrast Exposure | 777 (7%) | 200 (8%) | 0.0042 | 158 (10%) | 42 (6%) | 0.0042 |
|
| ||||||
| Hospital Length of Stay (d) | 1 (1 – 2) | 3 (2 – 6) | < 0.0011 | 3 (2 – 6) | 4 (2 – 8) | < 0.0011 |
Note: Values for categorical variables are given as number (percentage); for continuous variables, as median [interquartile range]. Conversion factor for serum creatinine in mg/dL to μmol/L, ×88.4.
AKI, acute kidney injury; Scr, serum creatinine; WBC, white blood cell
#
Other includes Asian, American Indian/Alaska Native and Native Hawaiian or Other Pacific Islander.
1
Wilcoxon test
2
Pearson test